Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
暂无分享,去创建一个
S. Shariat | P. Karakiewicz | D. Enikeev | B. Pradère | H. Mostafaei | M. Schmidinger | R. Sari Motlagh | K. Mori | P. Rajwa | A. Aydh | E. Laukhtina | F. Quhal | T. Yanagisawa | F. König
[1] J. Burke,et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. , 2021, The New England journal of medicine.
[2] S. Shariat,et al. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. , 2021, Urologic oncology.
[3] E. Frangou,et al. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] T. Powles,et al. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. , 2018, European urology.
[5] M. Casey,et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] J. Patard,et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. , 2018, European urology.
[7] R. Motzer,et al. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Manola,et al. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial , 2017, JAMA oncology.
[9] J. Patard,et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. , 2016, The New England journal of medicine.
[10] J. Manola,et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial , 2016, The Lancet.